Bromopyruvate

Drug Profile

Bromopyruvate

Alternative Names: 3-bromopyruvate; 3-bromopyruvic acid; 3-BrPA; PSL-001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johns Hopkins University
  • Developer PreScience Labs
  • Class Antineoplastics; Keto acids; Pyruvates; Small molecules
  • Mechanism of Action Alkylating agents; MASP2 protein inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Intra-arterial)
  • 24 Jul 2013 The US FDA approves IND application for bromopyruvate in Liver cancer
  • 01 Jan 2010 Preclinical trials in Cancer in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top